Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986449 Alone and with Nivolumab in Advanced Solid Tumors
NCT05888831Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Molecular Glues
- Countries
- 6
01
Overview
Phase 2, open-label trial of BMS-986449 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-Limiting Toxicities, Adverse Events and 3 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
BMS-986449
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05888831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888831.